{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T23:52:10Z","timestamp":1770508330435,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T00:00:00Z","timestamp":1575504000000},"content-version":"vor","delay-in-days":4631,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1093\/annonc\/mdl467","type":"journal-article","created":{"date-parts":[[2007,1,12]],"date-time":"2007-01-12T01:49:14Z","timestamp":1168566554000},"page":"647-651","source":"Crossref","is-referenced-by-count":19,"title":["Influence of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone on serologic parameters and clinical course in lymphoma patients with autoimmune diseases"],"prefix":"10.1016","volume":"18","author":[{"given":"S.","family":"W\u00f6hrer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Troch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Zwerina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Schett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Skrabs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Gaiger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Jaeger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.C.","family":"Zielinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Raderer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdl467_bb0010","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/jnci\/djj004","article-title":"Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype","volume":"98","author":"Smedby","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdl467_bb0015","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdl467_bb0020","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1200\/JCO.2004.04.020","article-title":"Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up","volume":"22","author":"Czuczman","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl467_bb0025","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdl467_bb0030","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/rheumatology\/40.2.205","article-title":"Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes","volume":"40","author":"Edwards","year":"2001","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 4","key":"10.1093\/annonc\/mdl467_bb0035","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1186\/ar1007","article-title":"B cell depletion in autoimmune disease","volume":"5","author":"Gorman","year":"2003","journal-title":"Arthritis Res Ther"},{"key":"10.1093\/annonc\/mdl467_bb0040","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/ard.61.10.883","article-title":"Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion","volume":"61","author":"Leandro","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1093\/annonc\/mdl467_bb0045","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdl467_bb0050","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project","volume":"89","author":"WHO","year":"1997","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdl467_bb0055","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl467_bb0060","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s11926-003-0011-y","article-title":"Lymphoproliferation in autoimmunity and Sjogren's syndrome","volume":"5","author":"Voulgarelis","year":"2003","journal-title":"Curr Rheumatol Rep"},{"key":"10.1093\/annonc\/mdl467_bb0065","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1182\/blood.V78.3.581.581","article-title":"Autoantibody activity of immunoglobulins isolated from B-cell follicular lymphomas","volume":"78","author":"Dighiero","year":"1991","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdl467_bb0070","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1586\/14737140.1.1.53","article-title":"Extranodal lymphoma of MALT-type: perspective at the beginning of the 21st century","volume":"1","author":"Raderer","year":"2001","journal-title":"Expert Rev Anticancer Ther"},{"issue":"8","key":"10.1093\/annonc\/mdl467_bb0075","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1136\/ard.2005.046193","article-title":"Long-term remission of Sjogren's syndrome-associated aggressive B-cell non-Hodgkin's lymphomas following administration of combined B-cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)","volume":"65","author":"Voulgarelis","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1093\/annonc\/mdl467_bb0080","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/00002281-200305000-00011","article-title":"The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets","volume":"15","author":"Dorner","year":"2003","journal-title":"Curr Opin Rheumatol"},{"key":"10.1093\/annonc\/mdl467_bb0085","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1046\/j.1365-2567.1999.00772.x","article-title":"Do self-perpetuating B lymphocytes drive human autoimmune disease?","volume":"97","author":"Edwards","year":"1999","journal-title":"Immunology"},{"key":"10.1093\/annonc\/mdl467_bb0090","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.4049\/jimmunol.167.8.4710","article-title":"T cell activation in rheumatoid synovium is B cell dependent","volume":"167","author":"Takemura","year":"2001","journal-title":"J Immunol"},{"issue":"Suppl 2","key":"10.1093\/annonc\/mdl467_bb0095","doi-asserted-by":"crossref","first-page":"ii18","DOI":"10.1093\/rheumatology\/keh619","article-title":"Panel discussion on B cells and rituximab: mechanistic aspects, efficacy and safety in rheumatoid arthritis and non-Hodgkin's lymphoma","volume":"44","author":"Panayi","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1093\/annonc\/mdl467_bb0100","first-page":"877","article-title":"High efficacy of rituximab in indolent HCV-related lymphoproliferative disorders associated with systemic autoimmune diseases","volume":"23","author":"Cervetti","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"10.1093\/annonc\/mdl467_bb0105","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/art.21260","article-title":"Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study","volume":"52","author":"Pijpe","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1093\/annonc\/mdl467_bb0110","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1023\/A:1008416911099","article-title":"Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma","volume":"9","author":"Berinstein","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdl467_bb0115","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/BF02981940","article-title":"Re-treatment of relapsed indolent B-cell lymphoma with rituximab","volume":"73","author":"Igarashi","year":"2001","journal-title":"Int J Hematol"},{"issue":"Suppl 4","key":"10.1093\/annonc\/mdl467_bb0120","doi-asserted-by":"crossref","first-page":"iv55","DOI":"10.1136\/ard.2005.042648","article-title":"Update on rituximab","volume":"64","author":"Eisenberg","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1093\/annonc\/mdl467_bb0125","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1182\/blood.V92.10.3505","article-title":"Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation","volume":"92","author":"Burt","year":"1998","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdl467_bb0130","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1200\/JCO.2002.11.088","article-title":"Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies","volume":"20","author":"Branson","year":"2002","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419378664?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419378664?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/18\/4\/647\/308061\/mdl467.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,12]],"date-time":"2025-01-12T22:32:38Z","timestamp":1736721158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419378664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["S0923753419378664"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdl467","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}